New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
12:43 EDTEBSEmergent BioSolutions secures U.S. commercial rights to influenza vaccine
Emergent BioSolutions announced that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the United States. The product candidate, a recombinant vaccine, has the potential to be produced quickly, at high yields and in a cost-effective manner. This license enables Emergent to fulfill the requirement to secure a pandemic influenza vaccine candidate under its contract with the Biomedical Advanced Research and Development Authority.
News For EBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
09:20 EDTEBSEmergent BioSolutions task order shows capabilities, says Summer Street
Summer Street says the task order from the U.S. government regarding the manufacturing of ZMapp for treating Ebola shows Emergent BioSolutions' manufacturing capabilities and its working relationship with the government. The firm estimates the contract could be in the multi-$100M range and come as early as Q4, but admits it does not know who will win it. Summer Street views Emergent as undervalued and reiterates a Buy rating on the name with a $35 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use